Hers Real Customer Outcomes: An Evidence-Based Review of Results, Costs, and Limitations

What Hers Actually Prescribes

Hers is not a pharmacy or a drug manufacturer. It is a telehealth platform that connects patients with licensed providers who write prescriptions filled by partner pharmacies. The clinical outcomes a subscriber can expect are determined by the specific medication prescribed, not the Hers brand itself.

Across its product lines, Hers providers prescribe well-studied, FDA-approved drugs: topical minoxidil for hair loss, SSRIs like sertraline for anxiety and depression, estradiol and progesterone for perimenopausal symptoms, and compounded semaglutide for weight loss. Each of these drugs has a clinical evidence base that exists independent of any telehealth platform. The question is not whether the drugs work. Published trials answer that. The real question is whether the Hers delivery model (asynchronous consultations, subscription pricing, no in-person exams) provides enough clinical oversight to match the outcomes seen in controlled settings.

A 2023 cross-sectional study published in JAMA Network Open found that telehealth prescribing for weight management medications increased 108-fold between 2019 and 2023, but that follow-up visit rates and lab monitoring lagged behind in-person care [1]. This gap matters. Drug efficacy in a trial with scheduled follow-ups does not automatically transfer to a subscription model where patients self-manage dosing adherence and side-effect reporting through a chat interface.

Weight Loss: Compounded Semaglutide Results

Hers offers compounded semaglutide, not brand-name Wegovy or Ozempic. This distinction matters for expected outcomes. Brand-name semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo in the STEP-1 trial (N=1,961) [2]. That is the reference standard.

Compounded versions use the same active molecule but are produced by 503A or 503B pharmacies under different manufacturing oversight. The FDA has repeatedly warned that compounded semaglutide products have not undergone FDA review for safety, efficacy, or quality [3]. No published randomized trial has evaluated compounded semaglutide head-to-head against the brand-name product. Patients may see similar results. They may not. The honest answer is that the data does not exist yet.

Hers prices its weight loss program starting around $149 to $195 per month, which undercuts the $1,000+ monthly list price of brand-name Wegovy for uninsured patients. Cost savings are real. But the Endocrine Society's 2024 clinical practice guideline on pharmacologic management of obesity recommends FDA-approved formulations as first-line therapy and does not endorse compounded alternatives [4].

Dr. Caroline Apovian, co-author of the Endocrine Society obesity guideline, stated: "Patients deserve to know whether the product they are injecting has been tested in rigorous clinical trials. Compounded GLP-1 agonists bypass that standard" [4]. Subscribers should weigh the cost savings against this regulatory gap.

Women's HRT: Estradiol, Progesterone, and Testosterone

Hers prescribes estradiol patches, oral micronized progesterone, and in some cases low-dose testosterone cream for perimenopausal and postmenopausal women. These are standard, guideline-concordant therapies. The 2022 Menopause Society position statement confirms that hormone therapy remains the most effective treatment for vasomotor symptoms, with estradiol reducing hot flash frequency by approximately 75% compared to placebo [5].

The WHI follow-up data, published across multiple analyses in JAMA, showed that estrogen-alone therapy in women aged 50 to 59 at initiation was associated with a lower risk of breast cancer (HR 0.78, 95% CI 0.63 to 0.96) and no increased cardiovascular risk during the intervention phase [6]. For combined estrogen-progestogen therapy, breast cancer risk modestly increased (HR 1.28) but absolute risk remained low at approximately 8 additional cases per 10,000 woman-years [6]. These numbers come from the WHI long-term follow-up published in JAMA, not from Hers marketing materials.

The concern with Hers for HRT is monitoring. Standard of care per the American College of Obstetricians and Gynecologists recommends baseline mammography, lipid panels, and periodic reassessment of symptom severity and bleeding patterns [7]. An asynchronous telehealth model can prescribe the right drug at the right dose. Whether it consistently catches abnormal bleeding patterns or orders timely follow-up labs is harder to verify from publicly available data. Patients on HRT through Hers should maintain a separate relationship with a gynecologist or primary care provider for imaging and lab work.

The testosterone cream offering fills a gap. Few traditional providers prescribe testosterone for women despite growing evidence that low-dose transdermal testosterone (300 mcg/day) improves sexual desire in postmenopausal women, as demonstrated in a Lancet Diabetes & Endocrinology meta-analysis of 36 RCTs covering 8,480 participants [8].

Hair Loss: Minoxidil and Spironolactone

Hers prescribes topical minoxidil 2% and oral spironolactone for female pattern hair loss (FPHL). Both have published evidence, though at different strength levels.

Topical minoxidil 2% is FDA-approved for FPHL. A Cochrane review of 47 trials found that minoxidil increased total hair count by a mean of 13.18 hairs per cm² compared to placebo at 24 weeks [9]. That is a modest, measurable effect. Results require 4 to 6 months of continuous use, and hair loss resumes within 3 to 6 months of stopping treatment. This is not a cure. It is maintenance therapy.

Spironolactone 100 to 200 mg daily is used off-label for FPHL. A retrospective study of 166 women treated with spironolactone for hair loss found that 74.3% showed clinical improvement at 12 months [10]. Spironolactone carries risks: hyperkalemia in patients with renal impairment, menstrual irregularity, and it is teratogenic (FDA category X). The American Academy of Dermatology guidelines note that potassium monitoring is recommended for women over 45 or those with cardiovascular risk factors [11].

Whether Hers consistently orders baseline potassium and renal function labs before starting spironolactone is a clinical governance question that publicly available information does not definitively answer. If you are prescribed spironolactone through Hers or any telehealth platform, request a basic metabolic panel before your first dose and at 4 to 6 weeks.

Mental Health Prescriptions: Scope and Limitations

Hers offers sertraline (Zoloft), buspirone, hydroxyzine, and propranolol for anxiety. It also prescribes sertraline and bupropion for depression. These are first-line agents per APA guidelines [12].

Sertraline response rates in major depression hover around 50 to 60% in published trials, with the STAR*D study (N=2,876) reporting a 36.8% remission rate with initial SSRI monotherapy [13]. That means roughly one in three patients achieves full remission on the first medication tried. The rest need dose adjustments, medication switches, or augmentation strategies. A platform that prescribes but does not provide structured psychiatric follow-up (PHQ-9 tracking, scheduled dose titrations, medication switch protocols) will underperform compared to integrated care.

Hers does not prescribe controlled substances. No benzodiazepines, no stimulants. This is appropriate for a telehealth-first model but limits its usefulness for patients with moderate-to-severe anxiety or ADHD comorbidity.

Dr. Michael Thase, professor of psychiatry at the University of Pennsylvania and STAR*D investigator, has noted: "The first prescription is only the beginning of depression treatment. Measurement-based care with regular symptom tracking is what separates adequate from excellent outcomes" [13]. Patients using Hers for mental health should track symptoms independently using validated scales (PHQ-9 for depression, GAD-7 for anxiety) and proactively message their provider when improvement stalls.

Cost Breakdown and Value Assessment

Hers pricing varies by category. Hair loss subscriptions start at approximately $25 per month for topical minoxidil. Mental health prescriptions run $25 to $85 per month including the consultation fee. HRT programs range from $50 to $120 monthly. The weight loss program with compounded semaglutide costs $149 to $195 per month.

For context, brand-name Wegovy lists at over $1,300 per month without insurance. Generic sertraline at a retail pharmacy costs approximately $4 to $15 per month through GoodRx. Generic topical minoxidil is available over the counter for $10 to $20 per month. Hers bundles the consultation, prescription, and shipping into one subscription, which adds convenience but may not add value for patients who already have a prescriber.

The value proposition is strongest for patients without insurance or without an established provider relationship, particularly for categories like testosterone cream for women or compounded semaglutide where traditional prescribing pathways are limited or expensive. It is weakest for generic medications readily available at any pharmacy. Paying $85 per month for a sertraline prescription that costs $4 at Costco only makes sense if you genuinely cannot access a provider through any other channel.

Hers vs. Alternatives: Comparative Positioning

Hers competes with Ro (formerly Roman), Noom Med, Calibrate, Found, and traditional telehealth platforms like Teladoc. Each has different strengths.

Ro offers similar D2C prescribing for both men and women with a comparable price structure. Calibrate pairs GLP-1 prescriptions with structured behavioral coaching and metabolic lab panels, at a higher price point ($159 to $299 per month) but with more clinical infrastructure. Found uses a combination approach with multiple medication classes. Noom Med combines cognitive behavioral therapy modules with GLP-1 prescriptions.

Hers differentiates on breadth: one platform covering hair, skin, mental health, HRT, and weight loss. This is convenient. But breadth can come at the cost of depth. A platform that prescribes across five clinical categories through asynchronous chat may not provide the same intensity of follow-up as a specialized program.

For HRT specifically, the AACE/ACE 2017 clinical practice guidelines recommend individualized therapy based on symptom severity, personal and family history, and patient preference, with regular reassessment at 3- to 6-month intervals [14]. Whether any asynchronous telehealth platform reliably achieves that cadence depends on the individual provider, not the platform's marketing.

Known Limitations and Red Flags

Several structural issues deserve attention before subscribing.

Cancellation friction is a consistent theme in public complaints filed with the Better Business Bureau and posted on review aggregators. Subscription auto-renewal, difficulty reaching support, and charges after cancellation requests appear repeatedly. These are business-model complaints, not clinical ones, but they affect patient experience.

Lab monitoring gaps are the more serious concern. Spironolactone requires potassium checks. HRT patients benefit from lipid panels and liver function tests. Semaglutide users should have baseline HbA1c, renal function, and a personal/family history screen for medullary thyroid carcinoma, as FDA labeling for semaglutide carries a boxed warning about thyroid C-cell tumors observed in rodent studies [15]. An asynchronous platform that does not require labs before prescribing is cutting a corner that matters.

No platform, including Hers, can substitute for a longitudinal clinical relationship with a provider who performs physical exams, reviews imaging, and integrates care across multiple conditions. Telehealth works best as a supplement, not a replacement, for primary care.

Patients considering Hers should confirm three things before subscribing: whether their specific medication requires baseline labs (and whether Hers orders them), whether the subscription terms allow month-to-month cancellation, and whether their state medical board licenses the prescribing provider. All three are verifiable. All three affect outcomes more than any marketing claim on the website.